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Wu and colleagues’ letter discusses the limitations of the use of a single sample per 
tumor to investigate neutral evolution in human cancers. Neutral tumor evolution 
describes the situation where there is no differential clonal selection amongst the 
population of cells within a cancer: all mutations that accrue during growth are 
passengers and all drivers were already present in the most recent common 
ancestor of the population.  
 
In Williams et al., 20161 we showed, using publically available data comprising a 
single sample from each of ≈900 tumors of 14 different types, that the patterns of 
subclonal mutations within many cancer genomes (≈35%) were precisely predicted 
by a mathematical formula describing neutral tumor evolution. In contrast, Ling et al. 
20152 performed multi-region whole-exome sequencing (23 samples) and high-
density targeted sequencing (286 samples) of a single hepatocellular carcinoma 
case, and by examining the mutation burden across the tumor, concluded that the 
entire malignancy was evolving neutrally.  
 
Wu and colleagues specifically question whether these two different approaches, 
namely analyzing intra-tumor heterogeneity within a sample versus dense multi-
region sampling, measure the same features of tumor evolution.   
 
Clearly, the key issue here is intra-tumor variation of the evolutionary process itself; 
specifically, whether some regions of a tumor are evolving neutrality and others are 
not. We agree with Wu and colleagues’ assertion that ‘local’ neutrality (e.g. within a 
single sample) does not necessarily imply ‘global’ neutrality across the whole tumor.  
 
However, there are two reasons to think that local and global neutrality are often 
correlated. 
 
First, as we discussed in Williams et al., our classifications of neutrality were 
consistent with the detection of subclonal driver mutations in existing multi-region 
sequencing studies: sub-clonal driver mutations and convergent evolution (consistent 
with ongoing selection) were often detected in ‘non neutral-like’ renal carcinoma3 and 
glioblastoma4, but  less frequently in ‘neutral-like’ colorectal cancer5. 
 
Second, we note that if a single sample comprises a large portion or section across 
the tumor, neutrality can be assessed with our method based on the analysis of 
within-sample variant allele frequencies (VAF) - mutations that are subclonal within 
the sample. Such a large sample can provide a ‘global’ view of neutral evolutionary 
dynamics and, to a degree with which a single large sample represents the tumor as 
whole, mitigates sampling bias. A similar approach has been successfully applied to 
deconvolute the clonal architecture of a single breast cancer case6. We note that the 
TCGA data we analyzed in our study is derived from large fresh-frozen resection 
specimens rather than small biopsies 
(http://cancergenome.nih.gov/cancersselected/biospeccriteria), thus reducing the 
sampling bias of our approach. However, we fully acknowledge that no single sub-
sampling strategy can fully capture the spatial architecture of a tumor and there is the 
need for extensive multi-region sequencing, which however remains at the moment 
impractical for large cohorts such as TCGA. 
 
Importantly, as we noted in our study, the depth of sequencing remains a limitation 
as it determines the time elapsed from the common ancestor (of the sampled 
population) where we can investigate neutral evolution, as new mutations become 
progressively rarer as the population grows. We agree that for low depth of 
sequencing, because under neutrality subclonal VAF is proportional to time, only a 
short period after the common ancestor can be studied and so only ‘global scale’ 
neutrality can be characterized, while the evolutionary dynamics of small populations 
remain inaccessible.  
 
Given these two points, we think it is unlikely that our analysis risks grossly 
misrepresenting the tendency for neutral evolution in a tumor type.  
 
While we fully agree that multi-region profiling reduces potential sampling bias (and 
indeed we use multi-region sequencing ourselves for this reason4,5), our method has 
the crucial advantage of allowing us to profile existing large cohorts (such as those of 
the ICGC and TCGA) and so to statistically address the issue of inter-patient 
variation7 within a tumor type. Clearly the optimum would be to combine the two 
approaches and perform multi-region sequencing on large cohorts, though this 
presents obvious financial and technical challenges. Indeed, our recent study shows 
multiple-sample analysis of VAF distributions leads to robust calling of neutrality8. 
Moreover, we note too that studying truly ‘local’ evolution requires the sequencing of 
very small and localized cancer cell populations, as we previously demonstrated5. 
 
Wu and colleagues also note that non-exponential tumor growth leads to a different 
pattern of subclonal variant allele frequencies in a neutrally growing tumor: boundary 
driven growth (described by N(t) ~ tγ) leads to the relationship: 
 𝑀(𝑓)~ 1𝑓 !!!! 
 
which may provide a good fit to the data in some cases, and so neutrality may be 
more common than we reported in Williams et al. Irrespective, in some of the 65% of 
non-neutral cases identified by our method, clear subclonal mutational clusters can 
be observed, and our computational simulations confirmed that such patterns are 
expected if differentially selected subclones are present (Supplementary Figure 11 in 
Williams et al.) – but we highlight that these clusters are not caused by boundary 
driven growth. The observations of ‘subclonal clusters’ is in line with previous 
studies6, and we note that amongst the TCGA samples we reanalysed in Williams et 
al., a previous analysis had detected subclonal peaks in the majority of cases9  
(though we note this analysis may have confused the 1/f tail with a low-frequency 
clone). Thus, irrespective of the underlying growth model, there is clear evidence of 
on-going selection in many tumors.  
 
In their letter, Wu et al. describe a model of selection (Equation [1]) that predicts that 
the variant allele frequency (VAF) distribution of a tumour sample will be 
indistinguishable both in the presence and absence of selection. We urge caution 
against using Equation [1] reported in the letter in the context of cancer as this model 
appears incompatible with our current knowledge of cancer biology. First, the model 
assumes a constant population size, which is of course inapplicable to cancer. 
Second, the model also assumes that a large majority of new subclonal mutations 
are under selection, leading to a continuum tail of variants at higher frequency than is 
expected by chance (neutrality). Importantly, this model of selection does not lead to 
the formation of distinct sub-clonal clusters in the variant allele frequency 
distribution6,10. We argue that such a large number of driver events at high frequency 
in the same cancer is highly unlikely, as most evidence points to a limited number of 
putative drivers per tumour5,11,12. In Williams et al. we developed a model of selection 
consistent with the current knowledge of cancer genomics, wherein subclones under 
strong selection arise infrequently during tumour growth, and where the majority of 
mutations are neutral passenger mutations. These dynamics do give rise to 
subclonal clusters of mutations, as reported by multiple studies6,10. The VAF 
distribution produced by these models consistently leads to rejection of the neutral 
null model. 
 
However, we agree with Wu and colleagues that weak selection is challenging to 
detect because it causes only slight changes in the clonal composition of the tumor 
that may be undetectable by current genomic profiling standards. Importantly, this is 
true for single sampling and multi-region profiling alike, and studies of n=1 tumours, 
such as the one conducted by the authors2, result in findings that are of uncertain 
generality. We acknowledge that it is very important at this stage to understand the 
precise signature of weak and strong selection, especially because clonal selection is 
often hard to define and produces complex patterns (hence one of the reasons why 
we focused in the original manuscript on understanding absence of selection, which 
is analytically tractable). This important topic is the focus of our current and future 
work13. Nevertheless, we note that the analysis in Williams et al. demonstrates that in 
a significant proportion of cases the null-model of neutral evolution cannot be 
rejected. 
 
In summary, we were very happy to see that two independent groups have now 
demonstrated neutral evolution in cancer, a concept that has been largely neglected 
by current genomic studies. While the difference between local and global neutrality 
should be fully addressed in future work, the salient point that we would like people 
to take away from Williams et al. is that in many cases neutral evolution is an entirely 
adequate description of the currently available data. 
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